Horizon's Tepezza Broke The Mold For 2020 Launches, But Still Got Snared By COVID-19
An Interview With CEO Tim Walbert
Tepezza was the breakout launch of the year and will change Horizon's growth trajectory, but for now it has been sidelined by a supply constraint caused by COVID-19 vaccine manufacturing.
You may also be interested in...
A Phase II trial of the anti-CD40 drug, which Horizon Therapeutics acquired in early 2021, met its primary endpoint in Sj
Thyroid eye disease drug Tepezza is now expected to generate more than $1.55bn in full year sales, despite missing a full quarter of revenue.
Regeneron's COVID-19 antibody cocktail helped drive 38% growth for the company, while Global Blood Therapeutics' Oxbryta continues to face headwinds and Horizon focuses on relaunches.